Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent can... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina +2 locations
Conditions: Sarcoma
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
Terminated
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of radiation therapy combined with chemotherapy, with or without surgery, is more effective in treating early cancer of the cervix. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery followed by different regimens of radiation therapy and chemotherapy wit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina +1 locations
Conditions: Cervical Cancer
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
Completed
Radiotherapy (RT) with concurrent chemotherapy represents the state of the art in curative intent treatment for locally advanced squamous carcinoma of the head and neck. Tumor hypoxia and high levels of angiogenesis (blood vessel formation) are associated with treatment failure. Preclinical models reveal that radiotherapy itself may induce tumor secretion of vascular endothelial growth factor (VEGF). Curability may consequently be reduced by multiple mechanisms. Over-expression of epidermal grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2013
Locations: Department of Radiation Oncology; Duke University Medical Center, Durham, North Carolina
Conditions: Head and Neck Cancer, Pharynx Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/07/2012
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina +2 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
Unknown
RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2009
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina +1 locations
Conditions: Lymphoma
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
Completed
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Durham, North Carolina
Conditions: Carcinoma, Non-Small-Cell Lung